Cargando...
An early look at selective RET inhibitor resistance: new challenges and opportunities
Two RET inhibitors, selpercatinib and pralsetinib, recently received approval for the treatment of advanced RET fusion-positive lung cancer. Acquired resistance to these inhibitors will be a major challenge. We have shown that resistance can emerge due to recurrent RET kinase domain mutations and, i...
Gardado en:
| Publicado en: | Br J Cancer |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Nature Publishing Group UK
2021
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8144197/ https://ncbi.nlm.nih.gov/pubmed/33758332 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-021-01344-7 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|